Abstract Prior Presentation & Publication Policies
Abstract Policies
Upon submission of an abstract to the 2012 Gastrointestinal Cancers Symposium, the First Author must agree to the following Abstract Policies on behalf of all parties involved with the abstract. The First Author is also responsible for communicating these policies to all co-authors. If any of these policies are violated, the involved abstract may be removed from the Symposium.
Confidentiality Policy
All First Authors of submitted abstracts must agree to the following:
Submitted Abstracts are considered both Confidential and Embargoed from the time of submission.
* For a study to be eligible for presentation, information contained in the abstract, as well as additional data and information to be presented about the study, may not be made public before the findings have been presented/published in compliance with the Embargo Policy.
The Confidentiality and Embargo Policies require that, prior to the embargo being lifted, the author, and coauthors of the research not:
1) publish the information or provide it to others who may publish it,
2) release the findings to news media, or
3) use the information for trading in the securities of any issuer, or provide it to others
who may use it for securities trading purposes.
The First Author is responsible for conveying this information to all parties.
*The one exception to these policies applies to abstract information that has been previously made public through presentation at another meeting. In these cases, the confidentiality and embargo policies appliy only to any updated information.
There is a formal exception process in place to address public disclosure in advance of the Symposium due to Securities and Exchange Commission requirements. To file an official Abstract Policy Exception Request, please contact ASCO directly.
Conflict of Interest Policy
In compliance with standards established by the ASCO Conflict of Interest Policy (J Clin Oncol. 2006 Jan 20;24[3]:519–521) and the Accreditation Council for Continuing Medical Education (ACCME), ASCO strives to promote balance, independence, objectivity, and scientific rigor through disclosure of financial and other interests, and identification and management of potential conflicts. According to the Society’s Conflict of Interest Policy, the following financial and other relationships must be disclosed: employment or leadership position, advisory role, stock ownership, honoraria, research funding, expert testimony, and other remuneration (J Clin Oncol. 2006 Jan 20;24[3]:520).
For clinical trials that began accrual on or after April 29, 2004, ASCO’s Policy places some restrictions on the financial relationships between a trial'sPrincipal Investigator (PI) and the trial's company sponsor (J Clin Oncol. 2006 Jan 20;24[3]:521). If a PI holds any restricted relationships, his or her abstract may be ineligible for placement in the 2012 Gastrointestinal Cancers Symposium unless the Ethics Committee grants an exception. Exceptions are generally not granted for PIs who have employment relationships with their trial's company sponsor or stock in the company sponsor exceeding $50,000. Abstracts that receive exceptions will be subject to additional management strategies, including but not limited to additional peer review, advance slide review, and session audits.
ASCO's Conflict of Interest Policy identifies the principal investigator of a clinical trial as "the individual with primary responsibility for the development of the protocol, the conduct of the trial, and the interpretation and dissemination of the trial data." Generally, it is expected that these responsibilities will rest with a single individual designated as the principal investigator and having the unique leadership responsibilities described in the policy. Certain abstracts that do not identify a principal investigator will be asked to answer additional questions.
NIH-funded trials are exempt from the Policy restrictions. ASCO will collect information on accrual initiation date, financial relationships of the principal investigator, and NIH funding upon abstract submission. It is the responsibility of the First Author to obtain disclosure information from all coauthors and to provide all disclosure of such interests and relationships through the Abstract Submitter program. Copies of the Disclosure Form can be sent to coauthors for completion and returned before submission of the abstract.
For more information on the ASCO Conflict of Interest Policy, the restrictions on PIs and additional questions for abstracts that do not identify a PI, please visit www.asco.org/rwi.
Prior Presentation or Publication Policy
If you intend to submit an abstract for the Annual Meeting of a cosponsoring organization, please read below the policy regarding whether or not abstracts presented at the Gastrointestinal Cancers Symposium will be eligible for presentation at the cosponsors’ Annual Meeting.
AGA Institute - Abstracts submitted to the Gastrointestinal Cancers Symposium will NOT be eligible for submission and presentation at the AGA annual meeting. However, abstracts that have been presented at the AGA Annual Meeting may be submitted to the 2012 Gastrointestinal Cancers Symposium.
ASCO – An abstract submitted for presentation at the 2012 Gastrointestinal Cancers Symposium may also be submitted for presentation at the 2012 ASCO Annual Meeting.
Note: If your abstract is to be considered for presentation at the ASCO Annual Meeting, you are encouraged to submit updated data. You will also need to resubmit your abstract using ASCO’s 2012 Annual Meeting Online Submitter.
ASTRO - Abstract submissions of papers presented at the Gastrointestinal Cancers Symposium will be accepted for consideration in ASTRO's 2012 Annual Meeting Scientific Program.
SSO - An abstract submitted for presentation at the Gastrointestinal Cancers Symposium may also be submitted for presentation at the 2011 SSO Annual Meeting.
Changes to Abstracts
First Authors may request corrections to rectify errors (i.e., typos, misspellings) within abstract submissions. Requests must be submitted by December 9, 2011.
 |
Requests for changes must be sent by the First Author to GISymposium@asco.org |
 |
Please call 571-483-1420 with any questions. |
- Please include the abstract ID, title, and an explanation of the changes to be made to the original text.
- Updates to original data will not be permitted, as changes are permissible only for the correction of errors.
Withdrawal of Abstracts
If a First Author chooses to withdraw his or her abstract for any reason, a request must be submitted by December 9, 2011.
|
Requests may be sent via e-mail to GISymposium@asco.org |
|
Requests may also be made by phone at 571-483-1420 |
- Additionally, a written request may be sent to the ASCO Education, Science, and Professional Development Department, 2318 Mill Road, Suite 800, Alexandria, VA 22314.
- Any abstract withdrawal requests received after this date will be considered on a case-by-case basis and cannot be assured removal from the Meeting Proceedings.